IFNγ-based therapy, while already employed as adjunctive immunotherapy in different bacterial, mycobacterial and fungal infections or sepsis-induced immunodepression, has been largely avoided in COVID-19 due to its potential proinflammatory effects [33,34]. This evidence concerns the gene IFNG and COVID-19.